Status:

COMPLETED

Effectiveness of Acupuncture and Doxylamine/Pyridoxine for Moderate to Severe Nausea and Vomiting in Pregnancy

Lead Sponsor:

Xiaoke Wu

Collaborating Sponsors:

Ningxia Hui Autonomous Region Hospital of TCM

Jiangxi Maternal and Child Health Hospital

Conditions:

Nausea and Vomiting of Pregnancy

Eligibility:

FEMALE

20-45 years

Phase:

PHASE3

Brief Summary

Nausea and vomiting in pregnancy (NVP) is one of the most common symptoms of pregnancy affecting 50-85% of women during the first half of pregnancy. Maternal morbidity is common and includes psycholog...

Detailed Description

Subjects will be randomized into one of the four treatment arms: A) active acupuncture (30 min /every day) + Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg)...

Eligibility Criteria

Inclusion

  • Women with 20-45 years of age;
  • PUQE score ≥6;
  • 7-14 weeks of gestation with viable fetus inside the uterine cavity confirmed by ultrasound dating;
  • Less than 20% weight loss.

Exclusion

  • Having major medical problems such as malignant tumor, acute or subacute severe hepatitis, severe aplastic anemia, idiopathic thrombocytopenic purpura, acute appendicitis, acute pancreatitis, TORCH syndrome, etc
  • Having chronic medical conditions such as poorly controlled diabetes, coronary heart disease, uncontrolled hypertension, etc
  • Coexistence of other diseases that cause vomiting such as infectious disease, gestational trophoblastic disease, etc
  • Having asthma, increased intraocular pressure, narrow-angle glaucoma, narrow peptic ulcer, pyloric obstruction, bladder neck obstruction, etc
  • Taking antiemetics such as vitamin B6, ondansetron, metoclopramide, prednisone, anti-vomiting Chinese medicine, etc., within the past week
  • Receiving conservative treatment such as dietary and lifestyle modification
  • Abnormal physical examination and laboratory tests (minor abnormalities in laboratory tests due to pregnancy vomiting, such as liver function and ions, are acceptable for inclusion)
  • Having mental handicaps or psychological disorders
  • Allergic to doxylamine, other ethanolamine-derived antihistamines, pyridoxine hydrochloride, or any inactive ingredient in diclectin
  • Using monoamine oxidase inhibitors
  • Driving or operating heavy machinery
  • Using alcohol or other central nervous system inhibitors

Key Trial Info

Start Date :

June 21 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2022

Estimated Enrollment :

352 Patients enrolled

Trial Details

Trial ID

NCT04401384

Start Date

June 21 2020

End Date

January 31 2022

Last Update

April 4 2022

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

First Affiliated Hospital of Heilongjiang Chinese Medicine University

Harbin, Heilongjiang, China

2

Heilongjiang provincial hospital

Harbin, Heilongjiang, China

3

Hegang Maternal and Child Health Hospital

Hegang, Heilongjiang, China

4

Affiliated Hospital of Jiamusi Medical University

Jiamusi, Heilongjiang, China